Ajay K. Wakhloo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Ajay K. Wakhloo has a total of 182 co-authors. Here are the top co-authors by number of shared publications:
- Peter Kan
Neurosurgery, The University of Texas Medical Branch at Galveston, Galveston, Texas, USA
9 shared publications - Adam Stephen Arthur
Department of Neurosurgery, University of Tennessee Health Science Center, Memphis, Tennessee, USA
5 shared publications - Edgar Andres Samaniego
University of Iowa
5 shared publications - Guilherme Dabus
Interventional Neuroradiology and Neuroendovascular Surgery, Miami Neuroscience Institute and Miami Cardiac & Vascular Institute - Baptist Hospital, Miami, Florida, USA
5 shared publications - Philip M. Meyers
Radiology and Neurological Surgery, Columbia University, New York, New York, USA
5 shared publications - Ricardo A. Hanel
Neurosurgery, Baptist Medical Center Jacksonville, Jacksonville, Florida, USA
5 shared publications
Latest Publications
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3475-3480
Cytoprotection for Acute Ischemic Stroke: Critical Appraisal of Recent Clinical Trials
Several phase III clinical trials testing cytoprotective approaches have recently been completed, and many of these studies report a clinical benefit. Reviewing the outcomes of these trials in light of their specific designs reveals intriguing results. Trials designed with shorter treatment time windows (≤24 hours) and featuring high rates of recanalization therapies predominantly show neutral outcomes, that is, no therapeutic benefit. Studies using later time points (>24 hours to 14 days) and often enrolling patients in whom recanalization is not or only infrequently established show clear treatment effects. These results challenge our current understanding of cytoprotective approaches, which are believed to primarily target the penumbra as the key to therapeutic success. The reasons for this are unclear. They may include other, potentially unknown mechanisms of action that improve clinical outcome even when applied within longer time windows rather than exerting acute cytoprotection. Here, we discuss such potential mechanisms, to what extent they could explain the results of recent cytoprotection trials, and review consequences for future translational and clinical research.
- 1 November 2026
- Published by Wolters Kluwer Health in Stroke
- Vol. 57 (11) , 3475-3480
Cytoprotection for Acute Ischemic Stroke: Critical Appraisal of Recent Clinical Trials
Several phase III clinical trials testing cytoprotective approaches have recently been completed, and many of these studies report a clinical benefit. Reviewing the outcomes of these trials in light of their specific designs reveals intriguing results. Trials designed with shorter treatment time windows (≤24 hours) and featuring high rates of recanalization therapies predominantly show neutral outcomes, that is, no therapeutic benefit. Studies using later time points (>24 hours to 14 days) and often enrolling patients in whom recanalization is not or only infrequently established show clear treatment effects. These results challenge our current understanding of cytoprotective approaches, which are believed to primarily target the penumbra as the key to therapeutic success. The reasons for this are unclear. They may include other, potentially unknown mechanisms of action that improve clinical outcome even when applied within longer time windows rather than exerting acute cytoprotection. Here, we discuss such potential mechanisms, to what extent they could explain the results of recent cytoprotection trials, and review consequences for future translational and clinical research.
- Open Access
- 10 July 2026
- Published by Springer Nature in Neuroradiology
- Vol. 68 (8) , 2353-2368
Balloon-assisted retrograde cerebral venography for enhanced visualization of the posterior and lateral dural venous sinuses: a feasibility study
Purpose: The venous phase of DSA offers inferior spatial resolution of cerebral venous anatomy due to contrast dilution. Likewise, retrograde cerebral venography (RCV) suffers from poor contrast retention due to contrast injection opposing the physiological direction of venous drainage. Therefore, this study aims to investigate the feasibility of balloon-assisted occlusion in improving visualization of cerebral venous anatomy during RCV. Methods: 17 consecutive patients who underwent balloon-assisted RCV between September 2023-June 2025 were included. A 9 F balloon guide catheter was positioned in the internal jugular vein or sigmoid sinus. Venography was performed before and after balloon inflation. Using standardized criteria, three neuroradiologists independently assessed visualization quality of venous structures, anatomical furthest extent of contrast enhancement, and pathology delineation. McNemar’s test was used for paired statistical comparisons between visualization with and without balloon occlusion. Results: Balloon inflation improved rates of “well visualized” pathology from 15.7% to 88.2% ( p < 0.001, OR = 29.04). The most distant structure visualized shifted from the ipsilateral sigmoid sinus without balloon occlusion (visible in 45.1% of cases) to the contralateral sigmoid sinus with balloon occlusion (visible in 72.5% of cases, p < 0.001). With balloon occlusion, homogenous opacification and clear margin delineation of both transverse and sigmoid sinuses showed significant improvements ( p < 0.001 for both). No procedure-related complications were observed in this limited cohort. Conclusion: In this feasibility experience, balloon-assisted occlusion during RCV improved visualization of the posterior and lateral dural venous sinuses and associated pathology. Future well-powered studies are needed to validate our findings and determine the definitive safety of this technique.
- 10 July 2026
- Published by Springer Nature in Neuroradiology
- Vol. 68 (8) , 2353-2368
Open AccessBalloon-assisted retrograde cerebral venography for enhanced visualization of the posterior and lateral dural venous sinuses: a feasibility study
Purpose: The venous phase of DSA offers inferior spatial resolution of cerebral venous anatomy due to contrast dilution. Likewise, retrograde cerebral venography (RCV) suffers from poor contrast retention due to contrast injection opposing the physiological direction of venous drainage. Therefore, this study aims to investigate the feasibility of balloon-assisted occlusion in improving visualization of cerebral venous anatomy during RCV. Methods: 17 consecutive patients who underwent balloon-assisted RCV between September 2023-June 2025 were included. A 9 F balloon guide catheter was positioned in the internal jugular vein or sigmoid sinus. Venography was performed before and after balloon inflation. Using standardized criteria, three neuroradiologists independently assessed visualization quality of venous structures, anatomical furthest extent of contrast enhancement, and pathology delineation. McNemar’s test was used for paired statistical comparisons between visualization with and without balloon occlusion. Results: Balloon inflation improved rates of “well visualized” pathology from 15.7% to 88.2% ( p < 0.001, OR = 29.04). The most distant structure visualized shifted from the ipsilateral sigmoid sinus without balloon occlusion (visible in 45.1% of cases) to the contralateral sigmoid sinus with balloon occlusion (visible in 72.5% of cases, p < 0.001). With balloon occlusion, homogenous opacification and clear margin delineation of both transverse and sigmoid sinuses showed significant improvements ( p < 0.001 for both). No procedure-related complications were observed in this limited cohort. Conclusion: In this feasibility experience, balloon-assisted occlusion during RCV improved visualization of the posterior and lateral dural venous sinuses and associated pathology. Future well-powered studies are needed to validate our findings and determine the definitive safety of this technique.
- 7 May 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Middle meningeal artery as a pathway to innovative treatments: ARISE III consensus recommendations
Background The middle meningeal artery (MMA) has emerged as an endovascular route for treating chronic subdural hematoma (CSDH), meningioma, and refractory headaches. The third ARISE roundtable convened experts from neurology, neurosurgery, neuroradiology, industry, and regulatory agencies to develop consensus guidance on current evidence for MMA-based therapies Methods Over 50 experts participated in a multi-stakeholder discussion. Evidence from randomized and observational studies, early-phase interventional series, and preclinical work was reviewed. Breakout groups focused on four domains: (1) MMA embolization (MMAE) for CSDH, (2) preoperative embolization of meningiomas, (3) MMA-targeted therapies for headache, and (4) transvascular access for endovascular drainage of subdural hematomas. Consensus recommendations were developed by a writing committee Results Randomized trials support MMAE as an adjunct to surgery or medical management for selected patients with non-acute, symptomatic CSDH to reduce recurrence, progression, and reoperation. Evidence remains insufficient to support MMAE for acute or asymptomatic subdural hematomas. For meningioma, observational data suggest that preoperative embolization in experienced centers can reduce blood loss and operative time and may delay recurrence in large, hypervascular tumors with predominant dural or external carotid supply; primary embolization and intra-arterial oncologic therapies remain investigational. Early series of MMA-directed lidocaine infusion for refractory migraine, status migrainosus, and post-subarachnoid hemorrhage headache show short-term benefit, highlighting the need for controlled trials. Preclinical and first-in-human studies of combined MMAE and transvascular drainage for CSDH demonstrate high technical success, rapid radiographic and clinical improvement, and no early recurrences Conclusion The MMA represents a vascular pathway for an expanding spectrum of neurointerventional therapies.
- 7 May 2026
- Published by BMJ in Journal of NeuroInterventional Surgery
Middle meningeal artery as a pathway to innovative treatments: ARISE III consensus recommendations
Background The middle meningeal artery (MMA) has emerged as an endovascular route for treating chronic subdural hematoma (CSDH), meningioma, and refractory headaches. The third ARISE roundtable convened experts from neurology, neurosurgery, neuroradiology, industry, and regulatory agencies to develop consensus guidance on current evidence for MMA-based therapies Methods Over 50 experts participated in a multi-stakeholder discussion. Evidence from randomized and observational studies, early-phase interventional series, and preclinical work was reviewed. Breakout groups focused on four domains: (1) MMA embolization (MMAE) for CSDH, (2) preoperative embolization of meningiomas, (3) MMA-targeted therapies for headache, and (4) transvascular access for endovascular drainage of subdural hematomas. Consensus recommendations were developed by a writing committee Results Randomized trials support MMAE as an adjunct to surgery or medical management for selected patients with non-acute, symptomatic CSDH to reduce recurrence, progression, and reoperation. Evidence remains insufficient to support MMAE for acute or asymptomatic subdural hematomas. For meningioma, observational data suggest that preoperative embolization in experienced centers can reduce blood loss and operative time and may delay recurrence in large, hypervascular tumors with predominant dural or external carotid supply; primary embolization and intra-arterial oncologic therapies remain investigational. Early series of MMA-directed lidocaine infusion for refractory migraine, status migrainosus, and post-subarachnoid hemorrhage headache show short-term benefit, highlighting the need for controlled trials. Preclinical and first-in-human studies of combined MMAE and transvascular drainage for CSDH demonstrate high technical success, rapid radiographic and clinical improvement, and no early recurrences Conclusion The MMA represents a vascular pathway for an expanding spectrum of neurointerventional therapies.
- Open Access
- 17 April 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (2) , e000222
Patient's Age Impact on Stroke Risk and Intracranial Aneurysm Occlusion: SCENT Flow Diverter Study—A Nonrandomized Clinical Trial on Large and Giant Aneurysms
BACKGROUND AND OBJECTIVES: The prospective single-arm nonrandomized SCENT (Surpass Intracranial Aneurysm Embolization System Pivotal) trial on flow diverter treatment of large and giant intracranial aneurysms (IA) was analyzed for patients' age and IA characteristics affecting stroke and occlusion rates over 5 years (Trial registration NCT01716117). METHODS: Impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as 65 years and younger vs older than 65. Kaplan–Meier estimates of time to both endpoints, stratified by age, were created. Univariate predictors of time-to-stroke were analyzed using univariable proportional hazards regression models. Limited bivariable modeling was also attempted. RESULTS: Of 180 patients with large or giant IA enrolled, 119 were 65 years and younger, whereas 61 were older than 65 years. The 3-year risk of stroke for the older than 65 years group (19.7%) was more than double that of the 65 years and younger group (9.2%), P = .047. No new strokes were reported between 3 and 5 years. Four patients (2.2%) experienced aneurysm rupture within the first week post-treatment, 3 being 65 years and younger and the fourth older than 65 (>.99). Complete IA occlusion within age strata at 1 year was: older than 65 60% (33/55), 65 years and younger 79.1% (87/110), P = .009, 3 years: older than 65 67.6% (25/37), 65 years and younger 82.5% (66/80), P = .071, and 5 years: older than 65 85.7% (18/21), 65 years and younger 91.8% (56/61), P = .417. CONCLUSION: Age older than 65 was associated with an increased risk of stroke and predictive of incomplete healing and increased time to healing.
- 17 April 2026
- Published by Wolters Kluwer Health in Neurosurgery Practice
- Vol. 7 (2) , e000222
Open AccessPatient's Age Impact on Stroke Risk and Intracranial Aneurysm Occlusion: SCENT Flow Diverter Study—A Nonrandomized Clinical Trial on Large and Giant Aneurysms
BACKGROUND AND OBJECTIVES: The prospective single-arm nonrandomized SCENT (Surpass Intracranial Aneurysm Embolization System Pivotal) trial on flow diverter treatment of large and giant intracranial aneurysms (IA) was analyzed for patients' age and IA characteristics affecting stroke and occlusion rates over 5 years (Trial registration NCT01716117). METHODS: Impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as 65 years and younger vs older than 65. Kaplan–Meier estimates of time to both endpoints, stratified by age, were created. Univariate predictors of time-to-stroke were analyzed using univariable proportional hazards regression models. Limited bivariable modeling was also attempted. RESULTS: Of 180 patients with large or giant IA enrolled, 119 were 65 years and younger, whereas 61 were older than 65 years. The 3-year risk of stroke for the older than 65 years group (19.7%) was more than double that of the 65 years and younger group (9.2%), P = .047. No new strokes were reported between 3 and 5 years. Four patients (2.2%) experienced aneurysm rupture within the first week post-treatment, 3 being 65 years and younger and the fourth older than 65 (>.99). Complete IA occlusion within age strata at 1 year was: older than 65 60% (33/55), 65 years and younger 79.1% (87/110), P = .009, 3 years: older than 65 67.6% (25/37), 65 years and younger 82.5% (66/80), P = .071, and 5 years: older than 65 85.7% (18/21), 65 years and younger 91.8% (56/61), P = .417. CONCLUSION: Age older than 65 was associated with an increased risk of stroke and predictive of incomplete healing and increased time to healing.
- 11 November 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (11) , 2167-2171
Emerging approaches in the management of intracranial hemorrhage: ARISE II consensus recommendations
Despite advances in the fundamental understanding of the pathophysiology of intracranial hemorrhage (ICH), many issues related to ICH management remain understudied with discrepancies in management. Given the high disease severity and prevalence, consensus recommendations are urgently needed to guide further research and management strategies. Thus, a group of clinical experts, industry leaders, and government representatives was assembled to examine emerging approaches in ICH management and their future impact on patient care. The timing of intervention within 24 hours and the role of minimally invasive evacuation, particularly for basal ganglia hemorrhage locations, were identified as key research focuses to guide future trial design. Mobile stroke units and artificial intelligence (AI) are promising technologies that streamline preoperative and triaging workflows and improve time to intervention. Efforts to further develop surgical technologies will be crucial to improve ICH visualization and evacuation. Further research, industry collaboration, and investment are needed to advance treatment frontiers and catalyze ICH research.
- 11 November 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (11) , 2167-2171
Emerging approaches in the management of intracranial hemorrhage: ARISE II consensus recommendations
Despite advances in the fundamental understanding of the pathophysiology of intracranial hemorrhage (ICH), many issues related to ICH management remain understudied with discrepancies in management. Given the high disease severity and prevalence, consensus recommendations are urgently needed to guide further research and management strategies. Thus, a group of clinical experts, industry leaders, and government representatives was assembled to examine emerging approaches in ICH management and their future impact on patient care. The timing of intervention within 24 hours and the role of minimally invasive evacuation, particularly for basal ganglia hemorrhage locations, were identified as key research focuses to guide future trial design. Mobile stroke units and artificial intelligence (AI) are promising technologies that streamline preoperative and triaging workflows and improve time to intervention. Efforts to further develop surgical technologies will be crucial to improve ICH visualization and evacuation. Further research, industry collaboration, and investment are needed to advance treatment frontiers and catalyze ICH research.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , 1636-1641
ARISE II Consensus on the Management of Intracranial Atherosclerotic Disease
Intracranial atherosclerotic disease (ICAD) is one of the leading causes of ischemic stroke worldwide. Despite advances in its diagnosis and management, there is no clear consensus on best practices to manage ICAD. This report summarizes the ARISE II (Roundtable Discussion With Industry and Stroke Experts) consensus in treating ICAD. The consensus underscored the importance of lifestyle modification and medical management in patients with ICAD. Patients who fail medical management are candidates for endovascular treatment. Open surgery is not recommended in patients who lack demonstrated hemodynamic insufficiency. The consensus also identified gaps in knowledge about the optimal duration of antithrombotics, the effect of the CYP2C19 genotype on medical management, the need for newer devices, and the standardization of antithrombotic protocols before stenting in an acute setting. Optical coherence tomography requires additional clinical data before defining its role in the diagnosis of ICAD.
- 1 June 2025
- Published by Wolters Kluwer Health in Stroke
- Vol. 56 (6) , 1636-1641
ARISE II Consensus on the Management of Intracranial Atherosclerotic Disease
Intracranial atherosclerotic disease (ICAD) is one of the leading causes of ischemic stroke worldwide. Despite advances in its diagnosis and management, there is no clear consensus on best practices to manage ICAD. This report summarizes the ARISE II (Roundtable Discussion With Industry and Stroke Experts) consensus in treating ICAD. The consensus underscored the importance of lifestyle modification and medical management in patients with ICAD. Patients who fail medical management are candidates for endovascular treatment. Open surgery is not recommended in patients who lack demonstrated hemodynamic insufficiency. The consensus also identified gaps in knowledge about the optimal duration of antithrombotics, the effect of the CYP2C19 genotype on medical management, the need for newer devices, and the standardization of antithrombotic protocols before stenting in an acute setting. Optical coherence tomography requires additional clinical data before defining its role in the diagnosis of ICAD.
- 7 May 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1078-1082
Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms
Background One-year and 3-year outcomes for the SCENT trial have previously been reported. However, 5-year (long-term) clinical outcomes have not previously been described. Methods In this multicenter prospective trial, 180 aneurysms in 180 subjects were treated with the Surpass flow diverter system across 26 sites. Patients were followed according to a standardized protocol at 1 month, 6 months, 1 year, 3 years, and 5 years. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale (mRS) scores, and complications were recorded. Results The 5-year clinical follow-up reported 119 subjects and nine deaths with a completion rate of 71.7%, with 5-year angiographic follow-up available in 82 of the surviving 171 patients (48%). Aneurysm occlusion (Raymond Class I) for those patients who underwent angiographic follow-up was 77.8% (91/117) and 90.2% (74/82) at 3 and 5 years. The primary effectiveness composite endpoint was achieved in 80.3% (57/71) of patients. The cumulative proportion of subjects experiencing new or worsening major ipsilateral stroke was 12.8% (23/180) at 36 months, with no new occurrences at 60 months. No late aneurysm ruptures occurred during the 5-year follow-up, and no additional retreatments occurred between 36 and 60 months. Between 3 and 5 years, 52 potential site-reported serious adverse events were sent to CEC for adjudication. Of these, nine were CEC-adjudicated to be serious and four were determined to be related to the procedure/device. Conclusions Five-year findings demonstrate the long-term safety and effectiveness of the Surpass flow diverter for intracranial aneurysm treatment, supported by high occlusion rates and low rates of delayed adverse events in this study. Trial registration number NCT01716117.
- 7 May 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 17 (10) , 1078-1082
Five-year results of the SCENT trial with Surpass flow diverters to treat large or giant wide-neck aneurysms
Background One-year and 3-year outcomes for the SCENT trial have previously been reported. However, 5-year (long-term) clinical outcomes have not previously been described. Methods In this multicenter prospective trial, 180 aneurysms in 180 subjects were treated with the Surpass flow diverter system across 26 sites. Patients were followed according to a standardized protocol at 1 month, 6 months, 1 year, 3 years, and 5 years. Aneurysm occlusion, in-stent stenosis, modified Rankin Scale (mRS) scores, and complications were recorded. Results The 5-year clinical follow-up reported 119 subjects and nine deaths with a completion rate of 71.7%, with 5-year angiographic follow-up available in 82 of the surviving 171 patients (48%). Aneurysm occlusion (Raymond Class I) for those patients who underwent angiographic follow-up was 77.8% (91/117) and 90.2% (74/82) at 3 and 5 years. The primary effectiveness composite endpoint was achieved in 80.3% (57/71) of patients. The cumulative proportion of subjects experiencing new or worsening major ipsilateral stroke was 12.8% (23/180) at 36 months, with no new occurrences at 60 months. No late aneurysm ruptures occurred during the 5-year follow-up, and no additional retreatments occurred between 36 and 60 months. Between 3 and 5 years, 52 potential site-reported serious adverse events were sent to CEC for adjudication. Of these, nine were CEC-adjudicated to be serious and four were determined to be related to the procedure/device. Conclusions Five-year findings demonstrate the long-term safety and effectiveness of the Surpass flow diverter for intracranial aneurysm treatment, supported by high occlusion rates and low rates of delayed adverse events in this study. Trial registration number NCT01716117.
- 23 April 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (3) , 773-781
Flow diversion for posterior circulation intracranial aneurysms: a systematic review and meta-analysis
Background: Posterior circulation (PC) aneurysms are associated with a higher risk of rupture. Flow diverters (FDs) are widely used for carotid intracranial aneurysms, but their role in PC aneurysms is less established. This meta-analysis examines the available literature on the safety and effectiveness of FDs for PC aneurysms. Method: We conducted a systematic search from database inception until October 2024. The primary effectiveness outcome was complete occlusion rate defined by the Raymond-Roy and/or O'Kelly-Marotta scales. Primary safety outcomes included thromboembolic event rates following implantation. Secondary outcomes included procedure-related mortality, good functional outcome (GFO), and retreatment. Pool estimates were calculated using a random-effect model. Subgroup analysis based on morphology and study design was also conducted. Results: A total of 42 studies met our inclusion criteria. A total of 1698 patients were treated with FDs for 1760 PC aneurysms. Among these cases, 47.6% were in the vertebral artery. Our pooled overall analysis of complete occlusion rates was 72.73% (P2 =67.2%), and the pooled thromboembolic events rate following implantation was 11.70% (P2 =70.5%). Additionally, the pooled mortality rate was 8.07% (P2 =61.5%), the retreatment rate was 6.59% (P2 =1%), and the pooled GFO rate was 83.99% (P2 =76%). Subgroup analysis revealed that fusiform-dolichoectatic had a complete occlusion rate of 48.29% (P2 =11.7%). Conclusion: FDs for PC aneurysms achieve generally adequate occlusion rates, except in dolichoectatic-fusiform subtypes. Despite achieving adequate occlusion rates, FD use was associated with higher thromboembolic events, mortality, and retreatment rates, which necessitates careful patient selection.
- 23 April 2025
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (3) , 773-781
Flow diversion for posterior circulation intracranial aneurysms: a systematic review and meta-analysis
Background: Posterior circulation (PC) aneurysms are associated with a higher risk of rupture. Flow diverters (FDs) are widely used for carotid intracranial aneurysms, but their role in PC aneurysms is less established. This meta-analysis examines the available literature on the safety and effectiveness of FDs for PC aneurysms. Method: We conducted a systematic search from database inception until October 2024. The primary effectiveness outcome was complete occlusion rate defined by the Raymond-Roy and/or O'Kelly-Marotta scales. Primary safety outcomes included thromboembolic event rates following implantation. Secondary outcomes included procedure-related mortality, good functional outcome (GFO), and retreatment. Pool estimates were calculated using a random-effect model. Subgroup analysis based on morphology and study design was also conducted. Results: A total of 42 studies met our inclusion criteria. A total of 1698 patients were treated with FDs for 1760 PC aneurysms. Among these cases, 47.6% were in the vertebral artery. Our pooled overall analysis of complete occlusion rates was 72.73% (P2 =67.2%), and the pooled thromboembolic events rate following implantation was 11.70% (P2 =70.5%). Additionally, the pooled mortality rate was 8.07% (P2 =61.5%), the retreatment rate was 6.59% (P2 =1%), and the pooled GFO rate was 83.99% (P2 =76%). Subgroup analysis revealed that fusiform-dolichoectatic had a complete occlusion rate of 48.29% (P2 =11.7%). Conclusion: FDs for PC aneurysms achieve generally adequate occlusion rates, except in dolichoectatic-fusiform subtypes. Despite achieving adequate occlusion rates, FD use was associated with higher thromboembolic events, mortality, and retreatment rates, which necessitates careful patient selection.
- Open Access
- 27 January 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (6) , 985
Author Correction: Endocisternal interfaces for minimally invasive neural stimulation and recording of the brain and spinal cord
- 27 January 2025
- Published by Springer Nature in Nature Biomedical Engineering
- Vol. 9 (6) , 985
Open AccessAuthor Correction: Endocisternal interfaces for minimally invasive neural stimulation and recording of the brain and spinal cord
- Open Access
Patient’s age impact on stroke risk and intracranial aneurysm occlusion - SCENT Flow Diverter trial on large and giant aneurysms
Importance: The multicenter, prospective, single-arm, non-randomized SCENT trial on flow diverter (FD) treatment for intracranial aneurysms (IA) was analyzed for patients’ age and IA characteristics impacting stroke and occlusion rates over 5 years. Design: The impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as ≤ 65 years versus >65 years. Product-limit (Kaplan-Meier) estimates of time to both endpoints, stratified by age group, were created. Univariate predictors of time to stroke were identified by including candidate variables in univariable proportional hazards regression models. Those variables found to be significant (p 65 years old. When parent artery stenosis and IA size were entered into a multiple-stepwise survival model, only stenosis remained as an independently significant predictor of time to stroke. At 3-year follow-up, there were a total of 23 strokes (12.8%), with 11 occurring in subjects ≤ 65 years; there was a greater risk for seniors (HR1.96, 95% CI 0.83-4.78). Four patients (4/180; 2.2%) experienced aneurysm rupture within the first week post-treatment, with 3 being ≤ 65 and the fourth aged 66 years. No new strokes were reported between 3 and 5 years. Complete IA occlusion rates for seniors were 60.0% (33/55), 67.6% (25/37), and 85.7% (18/21) at 12, 36, and 60 months, respectively, as compared to 79.1% (87/110), 82.5% (66/80), and 91.8% (56/61) for younger subjects. The time to complete IA occlusion was shorter in younger patients (HR1.53, 95% CI 1.07-2.19). Five subjects (2.8%) underwent retreatment, 2 in 60-year-old patients, and one each aged 64, 70, and 75. Conclusions and Relevance: Age > 65 and parent artery stenosis are related to an increased risk of major ipsilateral stroke in patients with intracranial aneurysms treated with a flow diverter. Age > 65 is also predictive of increased time to and incomplete healing. With demographic shifts, future treatments need to focus on expedited and improved healing. Trial Registration: https://www.clinicaltrials.gov NCT01716117 KEY POINTS: Question: What key variables, including patients’ age and intracranial aneurysm (IA) characteristics, determine procedural stroke risks in subjects treated for large or giant IA with flow-diverting stents? Findings: Aneurysm size and parent artery stenosis impacted occlusion rates and stroke risk, respectively. Over a 5-year observation period, the senior population had a significantly lower occlusion rate and higher risk for stroke, while the younger population was at higher risk for early aneurysm bleed following treatment. Meaning: With demographic shifts and a higher senior population being treated for IA, the stroke risk and incomplete occlusion rates need to be discussed with the patient before treatment.
Open AccessPatient’s age impact on stroke risk and intracranial aneurysm occlusion - SCENT Flow Diverter trial on large and giant aneurysms
Importance: The multicenter, prospective, single-arm, non-randomized SCENT trial on flow diverter (FD) treatment for intracranial aneurysms (IA) was analyzed for patients’ age and IA characteristics impacting stroke and occlusion rates over 5 years. Design: The impact on major ipsilateral stroke and IA occlusion was studied by stratifying age as ≤ 65 years versus >65 years. Product-limit (Kaplan-Meier) estimates of time to both endpoints, stratified by age group, were created. Univariate predictors of time to stroke were identified by including candidate variables in univariable proportional hazards regression models. Those variables found to be significant (p 65 years old. When parent artery stenosis and IA size were entered into a multiple-stepwise survival model, only stenosis remained as an independently significant predictor of time to stroke. At 3-year follow-up, there were a total of 23 strokes (12.8%), with 11 occurring in subjects ≤ 65 years; there was a greater risk for seniors (HR1.96, 95% CI 0.83-4.78). Four patients (4/180; 2.2%) experienced aneurysm rupture within the first week post-treatment, with 3 being ≤ 65 and the fourth aged 66 years. No new strokes were reported between 3 and 5 years. Complete IA occlusion rates for seniors were 60.0% (33/55), 67.6% (25/37), and 85.7% (18/21) at 12, 36, and 60 months, respectively, as compared to 79.1% (87/110), 82.5% (66/80), and 91.8% (56/61) for younger subjects. The time to complete IA occlusion was shorter in younger patients (HR1.53, 95% CI 1.07-2.19). Five subjects (2.8%) underwent retreatment, 2 in 60-year-old patients, and one each aged 64, 70, and 75. Conclusions and Relevance: Age > 65 and parent artery stenosis are related to an increased risk of major ipsilateral stroke in patients with intracranial aneurysms treated with a flow diverter. Age > 65 is also predictive of increased time to and incomplete healing. With demographic shifts, future treatments need to focus on expedited and improved healing. Trial Registration: https://www.clinicaltrials.gov NCT01716117 KEY POINTS: Question: What key variables, including patients’ age and intracranial aneurysm (IA) characteristics, determine procedural stroke risks in subjects treated for large or giant IA with flow-diverting stents? Findings: Aneurysm size and parent artery stenosis impacted occlusion rates and stroke risk, respectively. Over a 5-year observation period, the senior population had a significantly lower occlusion rate and higher risk for stroke, while the younger population was at higher risk for early aneurysm bleed following treatment. Meaning: With demographic shifts and a higher senior population being treated for IA, the stroke risk and incomplete occlusion rates need to be discussed with the patient before treatment.